- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | The 7MM atopic dermatitis market to experience growth, reaching $22.4bn by 2033 | ||
| Mi | Boehringer and Cue Biopharma to develop autoimmune therapies | ||
| 15.04. | Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts? | ||
| 15.04. | ESCMID Global 2025: Climate-informed infectious disease risk management | ||
| 15.04. | Coherus divests Udenyca franchise to Intas for up to $558.4m | ||
| 15.04. | How collaborative partnerships are driving progress in transformative cell and gene therapies (CGTs) | ||
| 15.04. | Ironwood's shares sink as FDA demands new trial for lead drug | ||
| 15.04. | Valneva's single-dose chikungunya vaccine authorised in Brazil | ||
| 15.04. | Reveal Genomics and Ona link on ONA-255 development for cancer | ||
| 14.04. | Verve Therapeutics' shares jump by more than 26% on Lilly-partnered gene therapy data | ||
| 14.04. | Pfizer drops obesity pill development after liver injury report | ||
| 14.04. | COPD market projected to grow to $30.2bn in the 7MM by 2033 | ||
| 14.04. | Roche's Columvi combo gains EC approval for DLBCL | ||
| 14.04. | Scancell shares up 6% after NHS partnership for fast-track cancer vaccine trial | ||
| 14.04. | Kyowa Kirin constructs drug manufacturing facility in Japan | ||
| 14.04. | Sandoz challenges Amgen's Enbrel patents in US antitrust lawsuit | ||
| 14.04. | BMS' Opdivo combo approved in US for hepatocellular carcinoma | ||
| 11.04. | Novartis commits $23bn to US manufacturing amid tariff threats | ||
| 11.04. | Pluri's immune cell expansion technologies gain patents | ||
| 11.04. | FDA to phase out animal testing with AI and lab-based models | ||
| 11.04. | AstraZeneca's oral breast cancer drug Truqap greenlit for NHS use | ||
| 11.04. | NMPA approves BBM and Takeda China's haemophilia B therapy | ||
| 11.04. | Can AI replace medical writers? Experts say not immediately | ||
| 11.04. | FDA approves Biocon Biologics' bevacizumab biosimilar for cancer | ||
| 10.04. | Keros Therapeutics considers sale amid investor pressure |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
